HOME > OUR WORLD > BUSINESS > FORMULATIONS BUSINESS

EUROPE

Building on our growth momentum, Lupin’s Europe revenues grew 11%, registering sales of Rs. 4,507 million. In line with its strategy of building a Specialty products portfolio while nurturing its Generics business in the region, the Company is exploring possibilities of additions to its existing portfolio acquired from Temmler Pharma GmbH & Co. in FY 2016. This includes Specialty products for an orphan indication which can be commercialised across Top 5 European markets. Lupin’s partnered business in Europe continued to perform strongly during FY 2017 on the back of niche product launches in the ARV segment. Lupin’s German subsidiary Hormosan, with a balanced mix of Generics and Specialty products, particularly focussing on Neurology, achieved a strong sales growth of 25% in FY 2017.

The Company filed three marketing authorization applications with European authorities in addition to getting six approvals during the year. Currently, the cumulative filings for Europe stand at 62 with 55 approvals received till date.

FORMULATIONS BUSINESS